Renvela, containing the active ingredient Sevelamer Carbonate, is a medication primarily used in the management of hyperphosphatemia (high levels of phosphate) in patients with chronic kidney disease (CKD) who are on dialysis. It belongs to a class of drugs known as phosphate binders, which work by binding to dietary phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream. Here is a detailed description:

1. Active Ingredient:

• Sevelamer Carbonate: Sevelamer Carbonate is a non-absorbed phosphate-binding polymer that works in the gut to bind phosphate from food, preventing its absorption into the bloodstream. It is a carbonate salt form of Sevelamer.

2. Indications:

• Hyperphosphatemia in CKD: Renvela is indicated for the control of serum phosphorus levels in patients with CKD who are on dialysis. Elevated phosphate levels are common in CKD patients due to decreased kidney function and can lead to complications such as bone disease and cardiovascular events.

3. Dosage:

• Renvela is available in tablet form, with each tablet containing 800 mg of Sevelamer Carbonate.
• The recommended dosage varies depending on the individual’s serum phosphorus levels and dietary phosphate intake. It is typically taken with meals or snacks.

4. Administration:

• Tablets should be taken orally with water, crushed, or chewed as directed by a healthcare professional.
• It is important to take Renvela with meals to maximize its phosphate-binding effects and reduce the risk of gastrointestinal side effects.

5. Effectiveness:

• Sevelamer Carbonate has been shown to effectively lower serum phosphate levels in patients with CKD on dialysis, helping to prevent complications associated with hyperphosphatemia.

6. Safety Profile:

• Renvela is generally well-tolerated when used as directed. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and abdominal pain.
• Rare but serious side effects may include bowel obstruction, perforation, and fecal impaction.

7. Contraindications:

• Renvela is contraindicated in individuals with a known hypersensitivity to Sevelamer Carbonate or any of the components of the medication.
• It should not be used in patients with bowel obstruction or ileus.

8. Precautions:

• Patients should be monitored regularly for serum phosphorus levels and other markers of kidney function while taking Renvela.
• Renvela may interact with other medications, so it is essential to inform healthcare providers about all current medications, including over-the-counter drugs and supplements.

9. Follow-Up Care:

• Patients receiving Renvela will likely undergo regular follow-up visits with their healthcare provider to monitor treatment response, assess serum phosphorus levels, and manage any side effects.

Renvela (Sevelamer Carbonate) is an important medication in the management of hyperphosphatemia in patients with CKD on dialysis, helping to reduce the risk of complications and improve overall outcomes. Treatment decisions should be made in consultation with a qualified healthcare professional, taking into account the individual patient’s health status, kidney function, dietary habits, and treatment goals.